Cosmo N.V. (“Cosmo”), a global leader in AI-driven healthcare and specialty pharmaceuticals, today reported financial results for the first half of 2026. During the period, the Company delivered double-digit growth in recurring revenues, advanced its dermatology pipeline toward regulatory submission, further strengthened the GI Genius™ platform with next-generation commercial and technological capabilities, and maintained a strong financial position. Cosmo ended the reporting period debt-free, with more than €205 million in cash, cash equivalents and investments, and reaffirms its full-year 2026 financial guidance.
– Recurring revenues from Winlevi® up 38%, Lialda® up 35%, and CDMO up 14% year-over-year
– Clascoterone Phase III 12-month data support chronic use, with regulatory submissions underway in the US and in Europe
– Debt-free with more than €205 million in cash, cash equivalents and investments
– Investor call today at 3 pm CET